Originally published as JCO Early Release 10.1200/JCO.2006.05.8198 on August 8 2006
Journal of Clinical Oncology, Vol 24, No 25 (September 1), 2006: pp. 4143-4149
© 2006 American Society of Clinical Oncology.
Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911
Oliver W. Press,
Joseph M. Unger,
Rita M. Braziel,
David G. Maloney,
Thomas P. Miller,
Michael LeBlanc,
Richard I. Fisher
From the Fred Hutchinson Cancer Research Center; Southwest Oncology Group Statistical Center, Seattle, WA; Oregon Health Sciences University, Portland, OR; Arizona Cancer Center, University of Arizona, Tucson, AZ; and the James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY
Address reprint requests to Southwest Oncology Group (S9911), Operations Office, 14980 Omicron Dr, San Antonio, TX 78245-3217; e-mail: pubs{at}swog.org
Purpose Advanced follicular lymphoma (FL) is incurable with conventional chemotherapy and radiotherapy, and optimal front-line management is controversial. This study was performed to determine the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy followed by tositumomab/iodine I-131 tositumomab.
Patients and Methods From 1999 to 2000, the Southwest Oncology Group (SWOG) conducted a phase II trial (S9911) to test a novel new regimen consisting of six cycles of CHOP chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I-131 tositumomab in 90 eligible patients with previously untreated, advanced-stage FL.
Results The overall response rate was 91%, including a 69% complete remission (CR) rate. After a median follow-up time of 5.1 years, the estimated 5-year overall survival (OS) rate was 87%, and the progression-free survival (PFS) rate was 67%. The 5-year estimates of OS and PFS were each 23% better (absolute difference) than the corresponding figures for patients treated on previous SWOG protocols with CHOP alone. An analysis according to the Follicular Lymphoma International Prognostic Index showed that 21% of patients had high-risk features, 44% had intermediate-risk features, and 34% had low-risk features. High-risk patients had worse OS than lower risk patients (P = .05), but differences in PFS were not statistically significant (P = .21). Serial monitoring of the t(14;18) translocation in bone marrow by polymerase chain reaction demonstrated that 32 of 38 informative patients obtained molecular CRs, including seven patients (18%) after CHOP and 24 additional patients (63%) after tositumomab/iodine I-131 tositumomab. (The timing of conversion of one patient was unclear.)
Conclusion A prospective, phase III, randomized Intergroup Trial is currently underway comparing the efficacy of the promising CHOP + tositumomab/iodine I-131 tositumomab regimen with the efficacy of CHOP + rituximab.
published online ahead of print at www.jco.org on August 7, 2006.
Supported in part by the following Public Health Service Cooperative Agreement Grants awarded by the National Cancer Institute, Department of Health and Human Services: CA38926, CA32102, CA46113, CA46282, CA20319, CA13612, CA11083, CA35261, CA35128, CA35192, CA37981, CA45377, CA67575, CA58861, CA35090, CA63844, CA35176, CA35996, CA46368, CA04919, CA46441, CA12644, CA58686, CA63850, CA35119, CA35431, CA58348, CA35281, CA76132, CA12213, CA76447, CA45560. Also supported in part by GlaxoSmithKline Inc.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Berasain, M. J. Perugorria, M. U. Latasa, J. Castillo, S. Goni, M. Santamaria, J. Prieto, and M. A. Avila
The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer
Experimental Biology and Medicine,
July 1, 2009;
234(7):
713 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Pagel, N. Orgun, D. K. Hamlin, D. S. Wilbur, T. A. Gooley, A. K. Gopal, S. I. Park, D. J. Green, Y. Lin, and O. W. Press
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
Blood,
May 14, 2009;
113(20):
4903 - 4913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Sharkey, O. W. Press, and D. M. Goldenberg
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy
Blood,
April 23, 2009;
113(17):
3891 - 3895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hochster, E. Weller, R. D. Gascoyne, T. M. Habermann, L. I. Gordon, T. Ryan, L. Zhang, N. Colocci, S. Frankel, and S. J. Horning
Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
J. Clin. Oncol.,
April 1, 2009;
27(10):
1607 - 1614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. McLaughlin
A Look in the Mirror
J. Clin. Oncol.,
March 10, 2009;
27(8):
1158 - 1159.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg, M. J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, et al.
Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
Blood,
February 12, 2009;
113(7):
1412 - 1421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Salles, N. Mounier, S. de Guibert, F. Morschhauser, C. Doyen, J.-F. Rossi, C. Haioun, P. Brice, B. Mahe, R. Bouabdallah, et al.
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Blood,
December 15, 2008;
112(13):
4824 - 4831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, J. Radford, A. Van Hoof, U. Vitolo, P. Soubeyran, H. Tilly, P. C. Huijgens, A. Kolstad, F. d'Amore, M. G. Diaz, et al.
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
J. Clin. Oncol.,
November 10, 2008;
26(32):
5156 - 5164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press
Evidence Mounts for the Efficacy of Radioimmunotherapy for B-Cell Lymphomas
J. Clin. Oncol.,
November 10, 2008;
26(32):
5147 - 5150.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Jacobs, S. H. Swerdlow, J. Kant, K. A. Foon, R. Jankowitz, S. R. Land, N. DeMonaco, J. Joyce, J. L. Osborn, T. L. Evans, et al.
Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma
Clin. Cancer Res.,
November 1, 2008;
14(21):
7088 - 7094.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin,
September 1, 2008;
58(5):
305 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med.,
August 7, 2008;
359(6):
613 - 626.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Plastaras, E. Glatstein, and S. J. Schuster
Commentary: Let the Tail Wag the Dog: The Case for Radioimmunotherapy of Low-Grade Follicular Lymphoma
Oncologist,
June 1, 2008;
13(6):
655 - 656.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist,
June 1, 2008;
13(6):
657 - 667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Bishton, R. J. Hicks, D. A. Westerman, M. H. Prince, M. Wolf, and J. F. Seymour
A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy
Haematologica,
May 1, 2008;
93(5):
789 - 790.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Thomas, J. P. O'Beirne, J. Furuse, A. T. C. Chan, G. Abou-Alfa, and P. Johnson
Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy
Ann. Surg. Oncol.,
April 1, 2008;
15(4):
1008 - 1014.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, M. Tani, S. Fanti, V. Stefoni, G. Musuraca, P. Castellucci, E. Marchi, M. Farsad, M. Fina, C. Pellegrini, et al.
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
Ann. Onc.,
April 1, 2008;
19(4):
769 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Friedberg
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma
Haematologica,
March 1, 2008;
93(3):
336 - 338.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Green, J. M. Pagel, A. Pantelias, N. Hedin, Y. Lin, D. S. Wilbur, A. Gopal, D. K. Hamlin, and O. W. Press
Pretargeted Radioimmunotherapy for B-Cell Lymphomas
Clin. Cancer Res.,
September 15, 2007;
13(18):
5598s - 5603s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res.,
September 15, 2007;
13(18):
5636s - 5642s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nabhan
It Is Follicular... . So, Why CHOP?
J. Clin. Oncol.,
March 1, 2007;
25(7):
915 - 916.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press and R. I. Fisher
In Reply
J. Clin. Oncol.,
March 1, 2007;
25(7):
916 - 917.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology,
January 1, 2007;
2007(1):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney
Follicular NHL: From Antibodies and Vaccines to Graft-versus-Lymphoma Effects
Hematology,
January 1, 2007;
2007(1):
226 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
